Vir Biotechnology, Inc. (VIR) 今日盘中股价大幅上涨5.82%，引起了市场的广泛关注。
消息面上，公司宣布与日本制药巨头安斯泰来（Astellas）达成了一项全球战略合作，共同开发靶向前列腺癌的T细胞接合器VIR-5500。根据协议，Vir Biotechnology将获得3.35亿美元的预付款和短期里程碑付款，并有资格获得高达13.7亿美元的后续开发、监管和销售里程碑付款，以及美国以外净销售额的两位数特许权使用费。
此次合作不仅为Vir Biotechnology带来了可观的即时资金流入，分担了后续研发成本，更借助安斯泰来在全球肿瘤领域的商业化能力，显著提升了VIR-5500这款潜在重磅疗法的市场前景。市场普遍认为，这项交易验证了Vir Biotechnology的PRO-XTEN®技术平台价值，并为其在实体瘤治疗领域的发展注入了强大动力，从而推动了股价的积极反应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.